The lawsuit, filed Tuesday in U.S. District Court in Delaware, is the latest in a series of patent challenges against ...

The latest trading session saw Medtronic (MDT) ending at $87.72, denoting a -0.45% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 0.38%. Meanwhile, ...

Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.

Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation ...

Luxembourg's Ministry of Health and Social Security has reported that a safety notice regarding certain models... }} ...

Medtronic reports Q3 (fiscal Q2) earnings on 11/19. The revenue estimate is $8.28 billion, while the EPS GAAP estimate is $0.94. Investors should pay particular attention to how the MiniMed recall ...

Sticks and stones may break my bones, but words will never hurt me.” While this mantra may help bruised egos on ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

The FDA recently announced critical recalls on several widely used medical devices, including Life2000 ventilators, Medtronic's MiniMed insulin pumps and Boston Scientific's Obsidio conformable ...

With this approval, Medtronic is now the first and only company with two PFA technologies available for patients with Afib. The PulseSelect™ Pulsed Field Ablation System, which was FDA approved ...

The affected products include all MiniMed 600 series and MiniMed 700 series insulin ... While no adverse effects were ...